Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
T.R.U.E. TEST (Thin-Layer Rapid Use Epicutaneous Patch Test) is a ready-to-use diagnostic patch test system developed by Mekos Laboratories AS. It is indicated for use as an aid in the diagnosis of allergic contact dermatitis in adults and children 6 years of age and older. The system consists of multiple test panels containing standardized allergens and allergen mixes (such as nickel, quaternium-15, and fragrances) embedded in a polyester patch. When applied to the skin for approximately 48 hours, these allergens trigger a localized delayed-type hypersensitivity reaction (Type IV) in sensitized individuals, allowing for the identification of specific contact allergens. It was FDA-approved in 1995 and serves as a standardized screening tool for common contact allergens.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on T.R.U.E. TEST.